Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases
I'm PortAI, I can summarize articles.
Tvardi Therapeutics Inc. has unveiled a corporate presentation detailing its progress in developing STAT3 inhibitors for fibrosis-driven diseases and cancers. The presentation highlights successful target engagement and disease modification in animal models, along with reductions in fibrosis and inflammation in clinical studies. The lead program, TTI-101, is under evaluation for idiopathic pulmonary fibrosis and hepatocellular carcinoma, with more data expected soon. Additionally, TTI-109, a prodrug in Phase 1 trials, aims to improve STAT3 inhibition delivery and tolerability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments